Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials

PURPOSE: Clinical trials of statins and other lipid-lowering therapies (LLTs) often report large inter-individual variations in their effects on low-density lipoprotein cholesterol (LDL-C). We evaluated apparent hyporesponsiveness to the proprotein convertase subtilisin/kexin type 9 inhibitor aliroc...

Descripción completa

Detalles Bibliográficos
Autores principales: Bays, Harold E., Rosenson, Robert S., Baccara-Dinet, Marie T., Louie, Michael J., Thompson, Desmond, Hovingh, G. Kees
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958153/
https://www.ncbi.nlm.nih.gov/pubmed/29627892
http://dx.doi.org/10.1007/s10557-018-6784-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958153/
https://www.ncbi.nlm.nih.gov/pubmed/29627892
http://dx.doi.org/10.1007/s10557-018-6784-z

Ejemplares similares